SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Down 78.9% in August

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 6,640 shares, a decline of 78.9% from the August 15th total of 31,402 shares. Based on an average daily volume of 300,155 shares, the days-to-cover ratio is presently 0.0 days.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ:SABSW traded up $0.01 during midday trading on Friday, reaching $0.03. The company’s stock had a trading volume of 47,595 shares, compared to its average volume of 77,775. The business’s fifty day simple moving average is $0.02 and its 200-day simple moving average is $0.02. SAB Biotherapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.20.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.